|
GSK PLC on Friday said a trial of two ovarian cancer treatments met its primary endpoint but did not meet a key secondary target. The First-Engot-OV44 phase III trial evaluated niraparib, sold under the brand name Zejula, and dostarlimab, sold under the brand name, Jemperli. The London-based pharmaceuticals firm said the trial met its primary endpoint of progression free survival demonstrating a statistically significant difference with the addition of dostarlimab to both standard of care carboplatin-paclitaxel chemotherapy and niraparib maintenance, with or without bevacizumab. However, GSK said the ‘key secondary endpoint of overall survival did not meet statistical significance’. Further analyses are ongoing and data will be shared with health authorities and presented at an upcoming scientific meeting, GSK added. Shares in GSK were 0.3% lower at 1,317.75 pence each in London on Friday morning. The wider FTSE 100 index was down 0.7%. Hesham Abdullah, global head of Oncology R&D, said: ‘As part of our focus in gynaecological cancers, we continue to evaluate the potential of this combination and look forward to sharing full results from the trial.’ The safety and tolerability profile was generally consistent with the known safety profiles of the individual agents, GSK said. Zejula is an oral, once-daily poly-ADP ribose polymerase inhibitor currently being evaluated in multiple pivotal trials. Jemperli, is a monoclonal antibody used as an anti-cancer medication. Copyright 2024 Alliance News Ltd. All Rights Reserved.
|
